Tyrosine kinase inhibitors (TKIs) that target epidermal growth factor receptor (EGFR) have
dramatically improved progression-free survival in non-small-cell lung cancer (NSCLC) …

Targeting the epidermal growth factor receptor (EGFR) pathway has become standard
practice for the treatment of advanced non-small-cell lung cancer. Compared with …

Patients with advanced stage non–small cell lung cancer with sensitizing epidermal growth
factor receptor (EGFR) mutations using EGFR tyrosine kinase inhibitors (TKIs) such as …

Tyrosine kinase inhibitors (TKIs) against the epidermal growth factor receptor (EGFR) are
the standard of care treatment in non-small cell lung cancer (NSCLC). TKIs are used first line …

The use of epidermal growth factor receptor (EGFR) inhibitors in several epithelial tumors
has increased considerably in recent years. Currently, they are approved in non-small cell …

The increased target specificity of epidermal growth factor receptor (EGFR) inhibitors
(EGFRIs) is associated with the reduction or abolition of nonspecific and haematopoietic …

Non-small-cell lung cancer (nsclc) has the highest prevalence of all types of lung cancer,
which is the second most common cancer and the leading cause of cancer-related mortality …

Introduction: Inhibition of the EGFR has emerged as a promising anticancer strategy, offering
improved efficacy and quality of life for patients affected by tumors. The overall level of …

The growing investigation and use of epidermal growth factor receptor (EGFR) inhibitors in
anticancer therapy has been motivated by their specificity for EGFR, which improves their …

Epidermal growth factor receptor inhibitors (EGFRIs) have demonstrated improved overall
survival in patients with non-small cell lung cancer, pancreatic cancer, and colorectal …